<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248753</url>
  </required_header>
  <id_info>
    <org_study_id>NL47065.068.13</org_study_id>
    <secondary_id>837002524</secondary_id>
    <nct_id>NCT02248753</nct_id>
  </id_info>
  <brief_title>Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department</brief_title>
  <acronym>ACWAS</acronym>
  <official_title>Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department (ACWAS-trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A symptomatic episode of the heart rhythm disorder 'atrial fibrillation' (AF) is a frequent
      reason for visits to the emergency department. Currently, in the majority of cases, immediate
      (electrical or pharmacological) cardioversion is chosen, while atrial fibrillation terminates
      spontaneously in 70% of the cases within 24 hours. A wait-and-see approach with rate-control
      medication only, and when needed cardioversion within 48 hours of onset of symptoms, could be
      effective, safe and more cost-effective than current standard of care and could lead to a
      higher quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>4 weeks</time_frame>
    <description>Presence of sinus rhythm on ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to conversion to sinus rhythm (Holter monitor)</measure>
    <time_frame>48 hours</time_frame>
    <description>Intervention group only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>Baseline, 4 weeks, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year follow-up of Major Adverse Cerebrovascular or Cardiovascular Events</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrence of Atrial Fibrillation</measure>
    <time_frame>1 month</time_frame>
    <description>Monitoring through handheld device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total health care and societal costs</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (AFEQT)</measure>
    <time_frame>Baseline, 4 weeks, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">437</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pharmacological cardioversion and/or electrical cardioversion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-and-see Approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rate control drugs only (metoprolol, verapamil or digoxin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmacological cardioversion - Flecainide</intervention_name>
    <arm_group_label>Standard Care</arm_group_label>
    <other_name>Flecainide</other_name>
    <other_name>Tambocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrical cardioversion</intervention_name>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <arm_group_label>Wait-and-see Approach</arm_group_label>
    <other_name>Selokeen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <arm_group_label>Wait-and-see Approach</arm_group_label>
    <other_name>Isoptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <arm_group_label>Wait-and-see Approach</arm_group_label>
    <other_name>Lanoxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmacological cardioversion - Amiodarone</intervention_name>
    <arm_group_label>Standard Care</arm_group_label>
    <other_name>Amiodarone</other_name>
    <other_name>Cordarone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECG with atrial fibrillation at the emergency department

          -  Heart rate &gt; 70bpm

          -  Symptoms most probable due to atrial fibrillation

          -  Duration of symptoms &lt; 36 hours

          -  &gt; 18 years of age

          -  Able and willing to sign informed consent

          -  Able and willing to use MyDiagnostick

        Exclusion Criteria:

          -  Signs of myocardial infarction on ECG

          -  Hemodynamic instability (systolic blood pressure &lt; 100mm Hg, heart rate &gt; 170 bpm)

          -  Presence of pre-excitation syndrome

          -  History of Sick Sinus Syndrome

          -  History of unexplained syncope

          -  History of persistent AF (episode of AF lasting more than 48 hours)

          -  Acute heart failure

          -  Currently enrolled in another clinical trial

          -  Deemed unsuitable for participation by attending physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry J Crijns, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elton Dudink, MD</last_name>
    <phone>+31433875119</phone>
    <email>elton.dudink@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harry Crijns, MD, PhD</last_name>
    <phone>+31433875093</phone>
    <email>hjgm.crijns@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Kamp, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Otto Kamp, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saskia van Roij</last_name>
    </contact>
    <investigator>
      <last_name>Marco Alings, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nard Rademakers, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Lukas Dekker, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nard Rademakers, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Verheij</last_name>
    </contact>
    <investigator>
      <last_name>Jurren van Opstal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Tieleman, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Tieleman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Hobbelt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle van Gelder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Hobbelt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medical Center</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Pisters, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Timo Lenderink, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Pisters, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alrijne Hospital</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lennert Kulker, MPA</last_name>
    </contact>
    <investigator>
      <last_name>Lennert Kulker, MPA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Kirchhof, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elton Dudink, MD</last_name>
      <phone>+31 43 3875119</phone>
      <email>elton.dudink@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Harry Crijns, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elton Dudink, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent van Dijk, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent van Dijk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelien de Zeeuw</last_name>
    </contact>
    <investigator>
      <last_name>Anho Liem, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toon Oomen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Toon Oomen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga de Lange-van Bruggen</last_name>
    </contact>
    <investigator>
      <last_name>Hemanth Ramanna, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth - TweeSteden Hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jos Widdershoven, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jos Widdershoven, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Bucx, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jeroen Bucx, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VieCuri Medical Center</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Holvoet</last_name>
    </contact>
    <investigator>
      <last_name>Joan Meeder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bob Weijs, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wouter Holvoet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Dudink E, Essers B, Holvoet W, Weijs B, Luermans J, Ramanna H, Liem A, van Opstal J, Dekker L, van Dijk V, Lenderink T, Kamp O, Kulker L, Rienstra M, Kietselaer B, Alings M, Widdershoven J, Meeder J, Prins M, van Gelder I, Crijns H. Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial. Am Heart J. 2017 Jan;183:49-53. doi: 10.1016/j.ahj.2016.09.009. Epub 2016 Oct 2.</citation>
    <PMID>27979041</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Electrical cardioversion</keyword>
  <keyword>Pharmacological cardioversion</keyword>
  <keyword>Rhythm control</keyword>
  <keyword>Rate control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

